Swiss global pharmaceutical giant Novartis recently broke ground on its new radioligand therapy (RLT) manufacturing site in Denton, part of its broader $23 billion investment in U.S. manufacturing and research.
When completed in 2028, the company’s first Texas‑based manufacturing facility will bring RLT medications closer to patients across the southern United States, becoming the fifth RLT site nationwide, Novartis said.
Novartis CEO Vas Narasimhan said radioligand therapy “is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale.”…